VEOPOZ

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Myasthenia GravisParoxysmal Nocturnal HemoglobinuriaGeographic AtrophyGeneralized Myasthenia GravisAge-Related Macular Degeneration (AMD)

102 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

1

Rituxan

Roche

Phase 3

72

Ultomiris

AstraZeneca

Phase 3

53

VEOPOZ

Regeneron

Phase 3

174

Vyvgart

Argenx

Phase 3

175

Cellcept

Roche

Phase 3

46

Zilbrysq

UCB

Phase 3

47

Soliris

AstraZeneca

Phase 3

48

Fabhalta

Johnson & Johnson

Phase 3

39

Arava

Sanofi

Phase 3

110

Rhapsido

Novartis

Phase 3

1Show 38 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Paroxysmal Nocturnal Hemoglobinuria7 trials

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

Recruiting·Regeneron·Phase 3·NCT05133531·190 enrolled

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Completed·Regeneron·Phase 2·NCT04888507·6 enrolled

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Terminated·Regeneron·Phase 3·NCT05131204·3 enrolled

Show 4 more trials

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

No longer available·Regeneron··NCT06028594

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Completed·Regeneron·Phase 2·NCT04811716·24 enrolled

An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Recruiting·Regeneron·Phase 3·NCT05744921·202 enrolled

A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy

Recruiting·Regeneron·Phase 3·NCT07154745·35 enrolled

MPA2 trials

Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

Approved for marketing·Regeneron··NCT06003881

Compassionate Use of Pozelimab

Approved for marketing·Regeneron··NCT05232110

Adult2 trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Completed·Regeneron·Phase 1·NCT04601844·19 enrolled

Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

Completed·Regeneron·Phase 1·NCT04491838·40 enrolled

Thrombosis1 trial

A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease

Recruiting·Regeneron·Phase 4·NCT07142343·5 enrolled

Geographic Atrophy1 trial

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Recruiting·Regeneron·Phase 1·NCT07230834·54 enrolled

4 more indications

Intravenous1 trial

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Completed·Regeneron·Phase 1·NCT04940364·30 enrolled

Efficacy and Safety1 trial

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Completed·Regeneron·Phase 2/3·NCT04209634·10 enrolled

Age-related Macular Degeneration (AMD)1 trial

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting·Regeneron·Phase 3·NCT06541704·975 enrolled

Generalized Myasthenia Gravis1 trial

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis

Active, not recruiting·Regeneron·Phase 3·NCT05070858·288 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News